SCHEMBL5392162

SCHEMBL5392162

[O-][N+]1(c2ccccc2)CCNCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ORAI1 Q96D31 1/20 0.38
ORAI2 Q96SN7 1/20 0.38
ORAI3 Q9BRQ5 1/20 0.38
TRPV6 Q9H1D0 1/20 0.38
HTR2C P28335 2/20 0.36
SIGMAR1 Q99720 4/20 0.35
OPRM1 P35372 1/20 0.35
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
ADRB1 P08588 1/20 0.35
HTR3A P46098 1/20 0.35
HTR3D Q70Z44 1/20 0.35
HTR3C Q8WXA8 1/20 0.35
SLC18A3 Q16572 1/20 0.35
HRH1 P35367 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
GBA1 P04062 1/20 0.32
HTR6 P50406 1/20 0.31
LMNA P02545 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL655078 0.78 HTR3A (0.39) HTR2CSIGMAR1HTR3EHTR3BADRB1
SCHEMBL1828313 0.78 LMNA (0.33) LMNA
SCHEMBL11224081 0.78 LMNA (0.33) LMNA
SCHEMBL11000922 0.77 HTR2C (0.42) HTR2CSIGMAR1HTR3EHTR3BADRB1
SCHEMBL6357142 0.77 CHRNB2 (0.41)
SCHEMBL4907271 0.76 ORAI1 (0.40) ORAI1ORAI2ORAI3TRPV6HTR2C
SCHEMBL76560 0.76 LMNA (0.32) KMT2ALMNA
Hydrochloric Acid SCHEMBL7459719 0.74 PABPC1 (0.32) OPRM1KMT2ALMNA
SCHEMBL9051047 0.74 CYP1A2 (0.44) ORAI1ORAI2ORAI3TRPV6MEN1
SCHEMBL10998296 0.74 CYP2A6 (0.35) HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253205-B2 Gem-disubstituted cyclohexane derivatives and their use as therapeutic agents MERCK SHARP & DOHME LIMITED (GB) 2007-08-07 US disclosed
EP-1286967-B1 CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME (GB) 2006-09-27 EP disclosed
US-7105507-B2 Cyclohexane derivatives and their use as therapeutic agents MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 US disclosed
US-20050261285-A1 Tetrahydropyran derivatives and their use as therapeutic agents DIRAT OLIVIER 2005-11-24 US disclosed
EP-1527062-A1 TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LTD. (GB) 2005-05-04 EP disclosed
WO-2004009573-A1 TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 2004-01-29 WO disclosed
US-20030236250-A1 Cyclohexane derivatives and their use as therapeutic agents MERCK SHARP & DOHME LTD. (GB) 2003-12-25 US disclosed
EP-1286967-A1 CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LTD. (GB) 2003-03-05 EP disclosed
WO-2001087838-A1 CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236250-A1 Cyclohexane derivatives and their use as therapeutic agents CNR2, CNR1, HTR1A ORAI1 707/4885ORAI2 1335/4885ORAI3 1844/4885
US-20050261285-A1 Tetrahydropyran derivatives and their use as therapeutic agents GRPR, GRM5, GRM6 ORAI1 1302/4885ORAI2 3029/4885ORAI3 2690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.